<h3>享受 TipRanks Premium 50% 折扣，放心投资</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
<p>Lexaria Bioscience (LEXX) 的最新更新已发布。</p>
<p>Lexaria Bioscience Corp. 宣布以纳斯达克规则下的市场价格进行 350 万美元的注册直接发行，涉及销售 2,661,600 股普通股，并同时发行未注册的认股权证。所得款项将支持 Lexaria 的研发、营运资金和一般企业用途，可能增强其市场地位并推动其创新药物递送技术的发展。</p>
<p>(LEXX) 股票的最新分析师评级为买入，目标价格为 4.00 美元。要查看 Lexaria Bioscience 股票的完整分析师预测列表，请参见 LEXX 股票预测页面。</p>
<p><strong>关于 Lexaria Bioscience 的更多信息</strong></p>
<p>Lexaria Bioscience Corp. 是一家全球药物递送平台的创新者，以其专利的 DehydraTECH 技术而闻名。该平台通过改善生物吸收、减少副作用和促进更有效地穿越血脑屏障，增强了各种药物的口服递送。公司运营着一个获得许可的内部研究实验室，并拥有 56 项全球授予的专利，拥有显著的知识产权组合。</p>
<p><strong>平均交易量：</strong> 577,635</p>
<p><strong>技术情绪信号：</strong> 卖出</p>
<p><strong>当前市值：</strong> 2978 万美元</p>

LEXX

<p>Lexaria Bioscience Corp. 宣布进行 350 万美元的注册直接发行，涉及销售 2,661,600 股股票和未注册的认股权证。这笔资金将用于支持研发、营运资金和公司用途，提升其药物递送技术。该公司以其 DehydraTECH 技术而闻名，该技术改善了药物的生物吸收和递送。最新的分析师评级为 LEXX 股票的买入，目标价格为 4.00 美元</p>

<h3>Claim 50% Off TipRanks Premium and Invest with Confidence</h3>
<div class="lb-trans"><h3>享受 TipRanks Premium 50% 折扣，放心投资</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
</div><p>The latest update is out from Lexaria Bioscience ( (LEXX) ).</p>
<div class="lb-trans"><p>Lexaria Bioscience (LEXX) 的最新更新已发布。</p>
</div><p>Lexaria Bioscience Corp. announced a $3.5 million registered direct offering priced at-the-market under Nasdaq rules, involving the sale of 2,661,600 shares of common stock and concurrent issuance of unregistered warrants. The proceeds will support Lexaria’s research and development, working capital, and general corporate purposes, potentially strengthening its market position and advancing its innovative drug delivery technologies.</p>
<div class="lb-trans"><p>Lexaria Bioscience Corp. 宣布以纳斯达克规则下的市场价格进行 350 万美元的注册直接发行，涉及销售 2,661,600 股普通股，并同时发行未注册的认股权证。所得款项将支持 Lexaria 的研发、营运资金和一般企业用途，可能增强其市场地位并推动其创新药物递送技术的发展。</p>
</div><p>The most recent analyst rating on (LEXX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Lexaria Bioscience stock, see the LEXX Stock Forecast page.</p>
<div class="lb-trans"><p>(LEXX) 股票的最新分析师评级为买入，目标价格为 4.00 美元。要查看 Lexaria Bioscience 股票的完整分析师预测列表，请参见 LEXX 股票预测页面。</p>
</div><p><strong>More about Lexaria Bioscience</strong></p>
<div class="lb-trans"><p><strong>关于 Lexaria Bioscience 的更多信息</strong></p>
</div><p>Lexaria Bioscience Corp. is a global innovator in drug delivery platforms, known for its patented DehydraTECH technology. This platform enhances the oral delivery of various drugs by improving bio-absorption, reducing side effects, and facilitating more effective delivery across the blood-brain barrier. The company operates a licensed in-house research laboratory and holds a significant intellectual property portfolio with 56 patents granted worldwide.</p>
<div class="lb-trans"><p>Lexaria Bioscience Corp. 是一家全球药物递送平台的创新者，以其专利的 DehydraTECH 技术而闻名。该平台通过改善生物吸收、减少副作用和促进更有效地穿越血脑屏障，增强了各种药物的口服递送。公司运营着一个获得许可的内部研究实验室，并拥有 56 项全球授予的专利，拥有显著的知识产权组合。</p>
</div><p><strong>Average Trading Volume:</strong> 577,635</p>
<div class="lb-trans"><p><strong>平均交易量：</strong> 577,635</p>
</div><p><strong>Technical Sentiment Signal:</strong> Sell</p>
<div class="lb-trans"><p><strong>技术情绪信号：</strong> 卖出</p>
</div><p><strong>Current Market Cap:</strong> $29.78M</p>
<div class="lb-trans"><p><strong>当前市值：</strong> 2978 万美元</p>
</div>

Lexaria Bioscience 通过直接发行筹集 350 万美元以加强研发